MX2009004615A - Derivados de eter como moduladores duales de los receptores de 5-hidroxitriptamina a (5-ht2a) y dopamina (d3). - Google Patents

Derivados de eter como moduladores duales de los receptores de 5-hidroxitriptamina a (5-ht2a) y dopamina (d3).

Info

Publication number
MX2009004615A
MX2009004615A MX2009004615A MX2009004615A MX2009004615A MX 2009004615 A MX2009004615 A MX 2009004615A MX 2009004615 A MX2009004615 A MX 2009004615A MX 2009004615 A MX2009004615 A MX 2009004615A MX 2009004615 A MX2009004615 A MX 2009004615A
Authority
MX
Mexico
Prior art keywords
receptors
ht2a
dual modulators
ether derivatives
disorders
Prior art date
Application number
MX2009004615A
Other languages
English (en)
Inventor
Georg Jaeschke
Luca Claudio Gobbi
Rosa Maria Rodriguez Sarmiento
Lucinda Steward
Olivier Roche
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38962066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009004615(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009004615A publication Critical patent/MX2009004615A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a moduladores duales de los receptores de la serotonina 5-HT2A y de la dopamina D3 que se representan mediante la fórmula general I: (ver fórmula (I)) en la que R1, R2 y A tienen los significados definidos en la descripción, a un proceso para su obtención, a sus sales farmacéuticamente aceptables, destinados a la fabricación de medicamentos para el tratamiento o la prevención de trastornos cognitivos, adicción a las drogas, depresión, ansiedad, dependencia de las drogas, demencias, desequilibro de la memoria, trastornos psicóticos, incluida la esquizofrenia, trastornos esquizoafectivos, enfermedad bipolar, manías, depresión psicótica y psicosis que comprenden la paranoia y los delirios.
MX2009004615A 2006-10-31 2007-10-22 Derivados de eter como moduladores duales de los receptores de 5-hidroxitriptamina a (5-ht2a) y dopamina (d3). MX2009004615A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06123274 2006-10-31
PCT/EP2007/061253 WO2008052899A1 (en) 2006-10-31 2007-10-22 Ether derivatives dual modulators of the 5-ht2a and d3 receptors

Publications (1)

Publication Number Publication Date
MX2009004615A true MX2009004615A (es) 2009-05-22

Family

ID=38962066

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004615A MX2009004615A (es) 2006-10-31 2007-10-22 Derivados de eter como moduladores duales de los receptores de 5-hidroxitriptamina a (5-ht2a) y dopamina (d3).

Country Status (18)

Country Link
US (1) US7795437B2 (es)
EP (1) EP2079693B1 (es)
JP (1) JP5087631B2 (es)
KR (1) KR101114651B1 (es)
CN (1) CN101535258B (es)
AR (1) AR063438A1 (es)
AU (1) AU2007316249B2 (es)
BR (1) BRPI0718127A2 (es)
CA (1) CA2667511A1 (es)
CL (1) CL2007003110A1 (es)
ES (1) ES2401663T3 (es)
IL (1) IL198157A0 (es)
MX (1) MX2009004615A (es)
NO (1) NO20091675L (es)
PE (1) PE20081342A1 (es)
RU (1) RU2009116509A (es)
TW (1) TW200826940A (es)
WO (1) WO2008052899A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101778844B (zh) * 2007-07-26 2013-01-02 弗·哈夫曼-拉罗切有限公司 5-ht2a和d3受体的双重调节剂
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
WO2011060363A2 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
US8877778B2 (en) 2010-12-15 2014-11-04 Hoffmann-La Roche Inc. Benzofurane compounds
US8722683B2 (en) * 2011-02-17 2014-05-13 Hoffmann La-Roche Inc. Benzodioxole piperazine compounds
US8921397B2 (en) 2011-05-04 2014-12-30 Hoffmann-La Roche Inc. Benzofurane-piperidine compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024264A (en) * 1974-08-15 1977-05-17 Ab Ferrosan Diphenylbutylpiperidines
GB1514718A (en) 1974-08-15 1978-06-21 Ferrosan Ab Diphenyl-butylpiperidines
JP2860689B2 (ja) 1990-03-14 1999-02-24 第一製薬株式会社 ピリミジン誘導体
EP0479601B1 (en) 1990-10-05 1999-12-15 Ajinomoto Co., Inc. Piperidine derivatives and their use as antiarrhythmic agents
CN1344266A (zh) 1999-03-26 2002-04-10 阿斯特拉曾尼卡有限公司 新的化合物
HUP0103986A2 (hu) 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
MXPA04006599A (es) 2001-12-04 2004-12-07 Actelion Pharmaceuticals Ltd 4-(piperidilo y pirrolidilo-aquilo-ureido)-quinolinas como antagonistas receptores de urotensina ii.
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
AU2003303678A1 (en) 2003-01-03 2004-08-10 Genzyme Corporation Urea derivatives and their use as anti-inflammatory agents
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CL2007003110A1 (es) 2008-06-13
TW200826940A (en) 2008-07-01
US20080103174A1 (en) 2008-05-01
PE20081342A1 (es) 2008-09-18
BRPI0718127A2 (pt) 2014-02-18
IL198157A0 (en) 2009-12-24
AU2007316249A1 (en) 2008-05-08
CA2667511A1 (en) 2008-05-08
AR063438A1 (es) 2009-01-28
ES2401663T3 (es) 2013-04-23
JP5087631B2 (ja) 2012-12-05
EP2079693A1 (en) 2009-07-22
RU2009116509A (ru) 2010-12-10
AU2007316249B2 (en) 2013-01-24
KR101114651B1 (ko) 2012-06-12
EP2079693B1 (en) 2013-02-27
US7795437B2 (en) 2010-09-14
CN101535258A (zh) 2009-09-16
NO20091675L (no) 2009-05-28
JP2010508319A (ja) 2010-03-18
KR20090075848A (ko) 2009-07-09
WO2008052899A1 (en) 2008-05-08
CN101535258B (zh) 2012-12-05

Similar Documents

Publication Publication Date Title
WO2009013212A3 (en) Dual modulators of 5-ht2a and d3 receptors
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
IN2012DN02968A (es)
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
TW200621762A (en) Novel compounds
MX2009004615A (es) Derivados de eter como moduladores duales de los receptores de 5-hidroxitriptamina a (5-ht2a) y dopamina (d3).
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
MX2012004848A (es) Compuestos heterociclicos triciclicos.
GEP20125538B (en) 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
MX347423B (es) Derivados de espiro-amina ciclica como moduladores de esfingosina 1 fosfato.
WO2009093209A3 (ru) 2-AЛKИЛAMИHO-3-APИЛCУЛЬФOHИЛ-ЦИKЛOAЛKAHO [e ИЛИ d] ПИPAЗOЛO [1,5-a] ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
TW200800943A (en) Indane derivatives as MCH receptor antagonists
HK1146049A1 (en) Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1
UA97036C2 (en) Cyclopropyl amine derivatives
IL201317A0 (en) Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists
DE602005021150D1 (de) 3-substituierte pyridinderivate als h3-antagonisten
TW200738693A (en) Substituted biaryls, process for their manufacture and use thereof as medicaments
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
WO2006050007A3 (en) Substituted indolizines and derivatives as cns agents
IL202236A0 (en) Prolinamide derivatives as nk3 antagonists
MX2007010400A (es) Nuevas sales de derivados de hexahidrofenantridina sustituida con 6-heterociclilo.
MX2009008323A (es) Derivados heterociclicos como receptores muscarinicos m3.

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration